1. Differences in integrated assessment and management of non-communicable diseases (NCDs) for people with HIV across the WHO European region. Kraef C, Singh S, Fursa O, Abutidze A, Rukhadze N, Mulabdic V, Yancheva N, Mehmeti M, Balayan T, Harxhi A, Trajanovska J, Mackintosh C, Duvivier C, Beniowski M, Jilich D, Reikvam DH, Tau L, Podlekareva D, Ryom L, Peters L, Kowalska J, Kirk O; EuroSIDA Study Group.
   HIV Med. 2024. Epub ahead of print. Abstract
    
2. SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among people with HIV across Europe in the multinational EuroSIDA cohort. Fursa O, Bannister W, Neesgaard B, Podlekareva D, Kowalska J, Benfield T, Gerstoft J, Reekie J, Rasmussen LD, Aho I, Guaraldi G, Staub T, Miro JM, Laporte JM, Elbirt D, Trofimova T, Sedlacek D, Matulionyte R, Oprea C, Bernasconi E, Hadžiosmanović V, Mocroft A, Peters L; EuroSIDA Study Group.
   HIV Med. 2024. Epub ahead of print. Abstract
    
3. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts. Byonanebye DM, Polizzotto MN, Maltez F, Rauch A, Grabmeier-Pfistershammer K, Wit F, De Wit S, Castagna A, d'Arminio Monforte A, Mussini C, Wasmuth JC, Fontas E, Abela I, Sarcletti M, Bansi-Matharu L, Jaschinski N, Peters L, Hosein SR, Vannappagari V, Cohen C, Bissio E, Mocroft A, Law M, Ryom L, Petoumenos K; RESPOND study group.
   Lancet HIV. 2024;11(5):e321-e332. Abstract
    
4. Anemia in liver transplant recipients: prevalence, severity, risk factors, and survival. Hegland NØ, Rezahosseini O, Pedersen CR, Møller DL, Bugge TB, Wareham NE, Arentoft NS, Hillingsø J, Lund TK, Rasmussen A, Nielsen SD.
   APMIS. 2024;132(3):152-160. Abstract
    
5. Differences in toll-like receptor ligand-induced cytokine concentrations before and after solid organ transplantation: A prospective, observational cohort study in a clinical setting. Møller DL, Sørensen SS, Perch M, Gustafsson F, Hald A, Knudsen AD, Abdulovski R, Arentoft NS, Lundgren J, Rasmussen A, Ostrowski SR, Nielsen SD.
   Scand J Immunol. 2024;99(2):e13337. Abstract
    
6. Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19. Jensen TO, Grandits GA, Jain MK, Murray TA, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker JV, Chen P, Dewar RL, Goodman AL, Hatlen TJ, Highbarger HC, Holodniy M, Lallemand P, Laverdure S, Leshnower BG, Looney D, Moschopoulos CD, Mugerwa H, Murray DD, Mylonakis E, Nagy-Agren S, Rehman MT, Rupert A, Stevens RA, Turville S, Weintrob A, Wick K, Lundgren J, Ko ER; ACTIV-3/TICO Study Group.
   J Infect Dis. 2024;229(3):671-679. Abstract
    
7. ExplaineR: an R package to explain machine learning models. Zargari Marandi R.
   Bioinform Adv. 2024;4(1):vbae049. Abstract
    
8. The association between single-nucleotide polymorphisms within type 1 interferon pathway genes and human immunodeficiency virus type 1 viral load in antiretroviral-naïve participants. Mørup SB, Leung P, Reilly C, Sherman BT, Chang W, Milojevic M, Milinkovic A, Liappis A, Borgwardt L, Petoumenos K, Paredes R, Mistry SS, MacPherson CR, Lundgren J, Helleberg M, Reekie J, Murray DD; INSIGHT FIRST and START study groups.
   AIDS Res Ther. 2024;21(1):27. Abstract
    
9. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration. Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, Günthard HF, Staehelin C, Zangerle R, Suarez I, Vehreschild JJ, Wit F, Menozzi M, d'Arminio Monforte A, Spagnuolo V, Pradier C, Carlander C, Suanzes P, Wasmuth JC, Carr A, Petoumenos K, Borgans F, Bonnet F, De Wit S, El-Sadr W, Neesgaard B, Jaschinski N, Greenberg L, Hosein SR, Gallant J, Vannappagari V, Young L, Sabin C, Lundgren J, Peters L, Reekie J; D:A:D cohort study; RESPOND cohort study.
   Clin Infect Dis. 2024:ciae228. Abstract
    
10. Trends in underlying causes of death in allogeneic hematopoietic cell transplant recipients over the last decade. Søborg A, Reekie J, Sengeløv H, Da Cunha-Bang C, Lund TK, Ekenberg C, Lodding IP, Moestrup KS, Lundgren L, Lundgren JD, Wareham NE.
    Eur J Haematol. 2024;112(5):802-809. Abstract
     
11. Long-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV. Pelchen-Matthews A, Mocroft A, Ryom L, Ross MJ, Sharma S, Coca S, Achhra A, Cornell E, Tracy R, Phillips A, Alonso MM, Toulomi G, Agan BK, Medland N, Wyatt CM; INSIGHT START Study Group.
    Kidney Int. 2024:S0085-2538(24)00313-2. Epub ahead of print. Abstract
     
12. Development of antibody levels and subsequent decline in individuals with vaccine induced and hybrid immunity to SARS-CoV-2. Reekie J, Stovring H, Nielsen H, Johansen IS, Benfield T, Wiese L, Stærke NB, Iversen K, Mustafa AB, Petersen KT, Juhl MR, Knudsen LS, Iversen MB, Andersen SD, Larsen FD, Baerends EAM, Lindvig SO, Rasmussen LD, Madsen LW, Bannister W, Jensen TO, Dietz LL, Ostrowski SR, Østergaard L, Tolstrup M, Lundgren JD, Søgaard OS; ENFORCE study group.
    Int J Infect Dis. 2024:107111. Abstract
     
13. The HepHIV 2023 Madrid conference: A call to action for political leadership in reaching the sustainable development goals on earlier testing and linkage to care for HIV, viral hepatitis, and sexually transmitted infections.  Simões D, Raben D, Moran AB, Imaz A, Stengaard AR, Raahauge A, Sullivan AK, Vaughan E, Brännström J, De Baetselier I, Platteau T, Casabona J, Del Amo J; 2023 HepHIV Conference Organising Committee and the EuroTEST Steering Committee.
    HIV Med. 2024. Epub ahead of print. Abstract
     
14. All-cause and AIDS-related mortality among people with HIV across Europe from 2001 – 2020: impact of antiretroviral therapy, and regional differences in a multicentre cohort study Kraef C, Tusch E, Singh S, Østergaard L, Fätkenheuer G, Castagna A, Moreno S, Kusejko K, Szetela B, Kuznetsova A, Tomažič J, Ranin J, Zangerle R, Mansson F, Marchetti G, De Wit S, Clarke A, Gerstoft J, Podlekareva D, Peters L, Reekie J, Kirk O, and the EuroSIDA Study Group.
    The Lancet Regional Health - Europe 2024;44: 100989. Abstract 
     
15. Chronic liver enzyme elevation and use of contemporary ARVs among persons living with HIV. Roen AO, Peters L, Wandeler G, van der Valk M, Zangerle R, Günthard HF, Wit F, Mussini C, De Wit S, d’Arminio Monforte A, Vehreschild JJ, Castagna A, Jaschinski N, Vannappagari V, Chen L, Tallada J, C’mar J, Mocroft A, Ryom L.
    Open Forum Infectious Diseases, 2024;11(6): ofae308. Abstract
16. Are C-reactive protein and procalcitonin safe and useful for antimicrobial stewardship purposes in patients with COVID-19? A scoping review. Williams A, Repetto E, Lebbie I, Khalife M, Jensen TO.
    Antimicrob Steward Healthc Epidemiol. 2024;4(1):e129. Abstract
     
17. Clinical characteristics of women with HIV in the RESPOND cohort: A descriptive analysis and comparison to men. Hutchinson J, Neesgard B, Kowalska J, Grabmeier-Pfistershammer K, Johnson M, Kusejko K, De Wit S, Wit F, Mussini C, Castagna A, Stecher M, Pradier C, Domingo P, Carlander C, Wasmuth J, Chkhartishvili N, Uzdaviniene V, Haberl A, d'Arminio Monforte A, Garges H, Gallant J, Said M, Schmied B, van der Valk M, Konopnicki D, Jaschinski N, Mocroft A, Greenberg L, Burns F, Ryom L, Petoumenos K.
    HIV Med. 2024. Epub ahead of print. Abstract
     
18. Deep immune cell phenotyping and induced immune cell responses at admission stratified by BMI in patients hospitalized with COVID-19: An observational multicenter cohort pilot study. Sejdic A, Hartling HJ, Gitz Holler J, Klingen Gjærde L, Matovu Dungu A, Engel Møller ME, Svanberg Teglgaard R, Utoft Niemann CU, Brooks PT, Mogensen TH, Weis N, Podlekareva D, Baum Jørgensen ML, Ortved Gang A, Stampe Hersby D, Hald A, Dam Nielsen S, Lebech AM, Helleberg M, Lundgren J, Træholt Franck K, Fischer TK, Barrella Harboe Z, Marquart HV, Rye Ostrowski S, Lindegaard B.
    Clin Immunol. 2024;267:110336. Abstract
     
19. Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation. Minculescu L, Reekie J, Petersen SL, Kornblit BT, Schjoedt I, Andersen NS, Andersen LP, Fischer-Nielsen A, Haastrup EK, Friis LS, Sengelov H.
    Acta Haematol. 2024;147(3):325-332. Abstract
     
20. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. Chou S, Alain S, Cervera C, Chemaly RF, Kotton CN, Lundgren J, Papanicolaou GA, Pereira MR, Wu JJ, Murray RA, Buss NE, Fournier M.
    J Infect Dis. 2024;229(2):413-421. Abstract
     
21. Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study. Jensen TO, Murray TA, Grandits GA, Jain MK, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker JV, Chen P, Dewar RL, Goodman AL, Hatlen TJ, Highbarger HC, Holodniy M, Lallemand P, Laverdure S, Leshnower BG, Looney D, Moschopoulos CD, Mugerwa H, Murray DD, Mylonakis E, Nagy-Agren S, Rehman MT, Rupert A, Stevens R, Turville S, Weintrob A, Wick K, Lundgren J, Ko ER; ACTIV-3/TICO Study Group.
    Lancet Microbe. 2024;5(6):e559-e569. Abstract
     
22. Evaluation of the feasibility and efficacy of point-of-care antibody tests for biomarker guided management of COVID-19. Reilly C, Mylonakis E, Dewar R, Young B, Nordwall J, Bhagani S, Chia PY, Davis R, Files C, Ginde AA, Hatlen T, Helleberg M, Hayanga A, Jensen TO, Jain MK, Kalomenidis I, Kim K, Lallemand P, Lindegaard B, Menon A, Ognenovska K, Poulakou G, Thorup Røge B, Rogers AJ, Shaw-Saliba K, Sandkovsky U, Trautner BW, Vasudeva SS, Vekstein A, Viens K, Wyncoll J, DuChateau B, Zhang Z, Wu S, Babiker AG, Davey V, Gelijns A, Higgs E, Kan V, Lundgren J, Matthews GV, Lane HC.
    J Infect Dis. 2024:jiae452. Epub ahead of print. Abstract
     
23. Impact of baseline SARS-CoV-2 load in plasma and upper airways on the incidence of acute extrapulmonary complications of COVID-19: a multicentric, prospective, cohort study. Jensen TO, Harper K, Gupta S, Liu ST, Dharan NJ, Baker JV, Pett SL, Shaw-Saliba K, Esmail A, Ho MQ, Almasri E, Dewar RL, Lundgren J, Vock DM.
    Clin Infect Dis. 2024:ciae469. Abstract
     
24. Integrase strand transfer inhibitor (INSTI) related changes in BMI and risk of diabetes: a prospective study from the RESPOND cohort consortium. Rupasinghe D, Bansi-Matharu L, Law M, Zangerle R, Rauch A, Tarr PE, Greenberg L, Neesgaard B, Jaschinski N, De Wit S, Wit F, Monforte AD, Fontas E, Castagna A, Stecher M, Brandes V, Florence E, Begovac J, Mussini C, Sönnerborg A, Abutidze A, Groh A, Vannappagari V, Cohen C, Young L, Hosein S, Ryom L, Petoumenos K.
    Clin Infect Dis. 2024:ciae406. Abstract
     
25. Longitudinal Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Immunity Over 2 Years Following Vaccination and Infection. Juhl AK, Dietz LL, Søgaard OS, Reekie J, Nielsen H, Johansen IS, Benfield T, Wiese L, Stærke NB, Jensen TØ, Olesen R, Iversen K, Fogh K, Bodilsen J, Madsen LW, Lindvig SO, Raben D, Andersen SD, Hvidt AK, Andreasen SR, Baerends EAM, Lundgren J, Østergaard L, Tolstrup M; ENFORCE Study Group.
    J Infect Dis. 2024;230(3):e605-e615. Abstract
     
26. Longitudinal Importance of the Soluble Receptor for Advanced Glycation End-Products in Non-intubated Hospitalized Patients with COVID-19 Pneumonia. Wick KD, Siegel L, Oldmixon C, Lundgren JD, Thompson BT, Jones C, Leroux C, Matthay MA.
    Am J Physiol Lung Cell Mol Physiol. 2024. Epub ahead of print. Abstract
     
27. Rate of response to initial antiretroviral therapy according to level of pre-existing HIV-1 drug resistance detected by next-generation sequencing in the strategic timing of antiretroviral treatment (START) study. Cozzi-Lepri A, Dunn D, Tostevin A, Marvig RL, Bennedbaek M, Sharma S, Kozal MJ, Gompels M, Pinto AN, Lundgren J, Baxter JD; INSIGHT START Study Group.
    HIV Med. 2024;25(2):212-222. Abstract
     
28. Risk of tuberculosis after initiation of antiretroviral therapy among persons with HIV in Europe. Johansen IS, Roen A, Kraef C, Martín-Iguacel R, Nemeth J, Fenner L, Zangerle R, Llibre JM, Miller RF, Suarez I, de Wit S, Wit F, Mussini C, Saracino A, Canetti D, Volny-Anne A, Jaschinski N, Neesgaard B, Ryom L, Peters L, Garges HP, Rooney JF, Podlekareva D, Mocroft A, Kirk O; RESPOND Study group.
    Int J Infect Dis. 2024;147:107199. Abstract
     
29. The use and impact of European Testing Week regional awareness campaigns to increase HIV and viral hepatitis testing coverage. Raben D, Kahama CB, Combs L, Stengaard A, Rockstroh JK, Simões D, Collins B; European Testing Week Working Group and the EuroTEST Steering Committee.
    HIV Med. 2024;25(1):154-160. Abstract
     
30. Trends in underlying causes of death in allogeneic hematopoietic cell transplant recipients over the last decade. Søborg A, Reekie J, Sengeløv H, Da Cunha-Bang C, Lund TK, Ekenberg C, Lodding IP, Moestrup KS, Lundgren L, Lundgren JD, Wareham NE.
    Eur J Haematol. 2024;112(5):802-809. Abstract
     
31. Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19. Aggarwal NR, Nordwall J, Braun DL, Chung L, Coslet J, Der T, Eriobu N, Ginde AA, Hayanga AJ, Highbarger H, Holodniy M, Horcajada JP, Jain MK, Kim K, Laverdure S, Lundgren J, Natarajan V, Nguyen HH, Pett SL, Phillips A, Poulakou G, Price DA, Robinson P, Rogers AJ, Sandkovsky U, Shaw-Saliba K, Sturek JM, Trautner BW, Waters M, Reilly C; ACTIV-3/TICO Study Group.
    Clin Infect Dis. 2024;78(6):1490-1503. Abstract
     
32. Predicting the next pandemic: VACCELERATE ranking of the World Health Organization's Blueprint for Action to Prevent Epidemics. Salmanton-García J, Wipfler P, Leckler J, Nauclér P, Mallon PW, Bruijning-Verhagen PCJL, Schmitt HJ, Bethe U, Olesen OF, Stewart FA, Albus K, Cornely OA; VACCELERATE Consortium.
    Travel Med Infect Dis. 2024;57:102676. Abstract
     
33. SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir. Singh K, Rubenstein K, Callier V, Shaw-Saliba K, Rupert A, Dewar R, Laverdure S, Highbarger H, Lallemand P, Huang ML, Jerome KR, Sampoleo R, Mills MG, Greninger AL, Juneja K, Porter D, Benson CA, Dempsey W, El Sahly HM, Focht C, Jilg N, Paules CI, Rapaka RR, Uyeki TM, Clifford Lane H, Beigel J, Dodd LE; Adaptive COVID-19 Treatment Trial (ACTT-1) Study Group Members.
    J Infect Dis. 2024;230(3):624-634. Abstract
     

IN PRESS